AbbVie partners with Mission for Alzheimer’s, Parkinson's

Nov 15, 2018

AbbVie has agreed to collaborate with Mission Therapeutics to develop deubiquitylating enzymes (DUBs) for the potential treatment of Alzheimer's disease and Parkinson's disease.

DUBs play a key role in maintaining cellular health by regulating the degradation of misfolded toxic proteins which are believed to cause impaired function and death of nerve cells in the brain. AbbVie and the Cambridge, England-based drug discovery and development company, Mission, are aiming to develop potential therapeutics that enable the degradation of toxic proteins and prevent their accumulation.

Under the terms of the agreement, both parties will collaborate during the research stage to identify specific DUBs and discover suitable compounds. AbbVie will then have the option to gain exclusive rights to develop and commercialize DUB inhibitors against up to four selected targets.

Read the press release

Want to get news like this in your inbox?  Subscribe to our eNewsletter here!

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments